Genprex, Inc. (NASDAQ: GNPX) is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (“NSCLC”). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. For more information, visit the company’s website at www.Genprex.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
For more information please visit https://www.BioMedWire.
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
LIXTE’s lead compound, LB-100, targets PP2A, a central regulator of cancer cell survival and treatment…
According to recent data, health expenditures in the U.S. reached $5.3 trillion in 2024. That figure equates…
Although CTCL may progress slowly in its early stages, it remains a chronic and ultimately…
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…
Researchers at the University of Chicago have identified a compound that has shown efficacy in shrinking tumors in…
Scientists have found that keeping circadian rhythms, the variations in body processes during the course…